Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 212

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)

Open access
Tony, Hans-Peter, Burmester, Gerd, Schulze-Koops, Hendrik, Grunke, Mathias, Henes, Joerg, Kötter, Ina, Haas, Judith, Unger, Leonore, Lovric, Svjetlana, Haubitz, Marion, Fischer-Betz, Rebecca, Chehab, Gamal, Rubbert-Roth, Andrea, Specker, Christof, Weinerth, Jutta, Holle, Julia, Müller-Ladner, Ulf, König, Ramona, Fiehn, Christoph, Burgwinkel, Philip, Budde, Klemens, Sörensen, Helmut, Meurer, Michael, Aringer, Martin, Kieseier, Bernd, Erfurt-Berge, Cornelia, Sticherling, Michael, Veelken, Roland, Ziemann, Ulf, Strutz, Frank, von Wussow, Praxis, Meier, Florian MP, Hunzelmann, Nico, Schmidt, Enno, Bergner, Raoul, Schwarting, Andreas, Eming, Rüdiger, Hertl, Michael, Stadler, Rudolf, Schwarz-Eywill, Michael, Wassenberg, Siegfried, Fleck, Martin, Metzler, Claudia, Zettl, Uwe, Westphal, Jens, Heitmann, Stefan, Herzog, Anna L, Wiendl, Heinz, Jakob, Waltraud, Schmidt, Elvira, Freivogel, Klaus, Dörner, Thomas, GRAID investigators · 2011 · Arthritis Research & Therapy

Abstract

Introduction: Evidence from a number of open-label, uncontrolled studies has suggested that rituximab may benefit patients with autoimmune diseases who are refractory to standard-of-care. The objective of this study was to evaluate the safety and clinical outcomes of rituximab in several standard-of-care-refractory autoimmune diseases (within rheumatology, nephrology, dermatology and neurology) other than rheumatoid arthritis or non-Hodgkin's lymphoma in a real-life clinical setting. Methods: Patients who received rituximab having shown an inadequate response to standard-of-care had their safety and clinical outcomes data retrospectively analysed as part of the German Registry of Autoimmune Diseases. The main outcome measures were safety and clinical response, as judged at the discretion of the investigators. Results: A total of 370 patients (299 patient-years) with various autoimmune diseases (23.0% with systemic lupus erythematosus, 15.7% antineutrophil cytoplasmic antibody-associated granulomatous vasculitides, 15.1% multiple sclerosis and 10.0% pemphigus) from 42 centres received a mean dose of 2,440 mg of rituximab over a median (range) of 194 (180 to 1,407) days. The overall rate of serious infections was 5.3 per 100 patient-years during rituximab therapy. Opportunistic infections were infrequent across the whole study population, and mostly occurred in patients with systemic lupus erythematosus. There were 11 deaths (3.0% of patients) after rituximab treatment (mean 11.6 months after first infusion, range 0.8 to 31.3 months), with most of the deaths caused by infections. Overall (n = 293), 13.3% of patients showed no response, 45.1% showed a partial response and 41.6% showed a complete response. Responses were also reflected by reduced use of glucocorticoids and various immunosuppressives during rituximab therapy and follow-up compared with before rituximab. Rituximab generally had a positive effect on patient well-being (physician's visual analogue scale; mean improvement from baseline of 12.1 mm). Conclusions: Data from this registry indicate that rituximab is a commonly employed, well-tolerated therapy with potential beneficial effects in standard of care-refractory autoimmune diseases, and support the results from other open-label, uncontrolled studies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/ar3337

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

Metadata

Authors
Tony, H.-P., Burmester, G., Schulze-Koops, H., Grunke, M., Henes, J., Kötter, I., Haas, J., Unger, L., Lovric, S., Haubitz, M., Fischer-Betz, R., Chehab, G., Rubbert-Roth, A., Specker, C., Weinerth, J., Holle, J., Müller-Ladner, U., König, R., Fiehn, C., Burgwinkel, P., Budde, K., Sörensen, H., Meurer, M., Aringer, M., Kieseier, B., Erfurt-Berge, C., Sticherling, M., Veelken, R., Ziemann, U., Strutz, F., von Wussow, P., Meier, F. M., Hunzelmann, N., Schmidt, E., Bergner, R., Schwarting, A., Eming, R., Hertl, M., Stadler, R., Schwarz-Eywill, M., Wassenberg, S., Fleck, M., Metzler, C., Zettl, U., Westphal, J., Heitmann, S., Herzog, A. L., Wiendl, H., Jakob, W., Schmidt, E., Freivogel, K., Dörner, T., & GRAID investigators
Venue
Arthritis Research & Therapy
Published
2011-05-13
Volume
13
Issue
3
Pages
R75-R75
ISSN
1478-6354 (ISSN-L)
OpenAlex
W2143000096
Cited by
212
References
2
FWCI
13.33
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.